The combination of accelerating revenue growth, improving profitability, and multiple near-term catalysts (KarXT launch, VYVGART regulatory decisions, zoci data readouts) positions Zai Lab for sustained outperformance. The company's transition toward profitability while advancing its pipeline suggests strong execution capability.
Price Chart
Executive Summary
Zai Lab reported strong financial results for Q4 and full-year 2025, with total revenue growing 17% YoY to $127.6 million in Q4 and 15% YoY to $460.2 million for the full year. The company achieved a 41% reduction in net loss to $175.5 million, driven by revenue growth outpacing expenses and improved foreign exchange performance. Key developments include the approval and upcoming commercial launch of KarXT in China, advancement of its global oncology pipeline including zoci, and positive clinical data for VYVGART in ocular myasthenia gravis.
Key Financial Metrics
Key Facts
- Total revenue grew 17% YoY to $127.6 million in Q4 2025 and 15% YoY to $460.2 million for full-year 2025
- Net loss decreased 32% YoY to $175.5 million for full-year 2025, with Q4 net loss down 38% to $50.4 million
- KarXT approved in China for schizophrenia treatment and commercial launch planned for H1 2026
- VYVGART Phase 3 trial met primary endpoint for ocular myasthenia gravis with statistically significant improvement
- FDA accepted Priority Review for VYVGART sBLA for seronegative gMG with PDUFA date of May 10, 2026
Financial Impact
Revenue growth of $61.2 million YoY with $81.6 million reduction in net loss
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| ZEJULA | $189.0M | +1.0% |
| VYVGART and VYVGART Hytrulo | $94.2M | +1.0% |
| XACDURO | $22.9M | +593.0% |
| NUZYRA | $60.8M | +41.0% |
Risk Factors
- Continued operating losses despite improvement
- Dependence on successful commercialization of new products like KarXT
- Pipeline development risks for zoci and other candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001704292-26-000014 |
| Document: zlab-20260226.htm | 0001704292-26-000014 |
| Document: 0001704292-26-000014-index-headers.html | 0001704292-26-000014 |
| Document: 0001704292-26-000014-index.html | 0001704292-26-000014 |
| Document: 0001704292-26-000014.txt | 0001704292-26-000014 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Insider Cluster | $26.01 $26.08 | โฒ +0.27% | โผ โ0.20% | $24.33 (โ6.46%) |
Aug 13, 2026 7w ago | Insider Cluster | $26.03 $26.02 | โผ โ0.04% | โฒ +1.93% | $24.33 (โ6.53%) |
Aug 13, 2026 7w ago | Insider Cluster | $26.03 $26.02 | โผ โ0.04% | โฒ +1.93% | $24.33 (โ6.53%) |
Aug 12, 2026 7w ago | 144 | $25.49 $26.72 | โฒ +4.83% | โฒ +5.27% | $24.33 (โ4.55%) |
Jul 1, 2026 13w ago | Insider Cluster | $19.15 $19.35 | โฒ +1.04% | โฒ +0.78% | $24.33 (+27.05%) |
Jun 29, 2026 13w ago | Insider Cluster | $19.00 $19.08 | โฒ +0.42% | โผ โ0.18% | $24.33 (+28.05%) |
Jun 11, 2026 16w ago | Institutional Cluster | $17.64 $17.88 | โผ โ1.36% | โผ โ0.93% | $24.33 (โ37.93%) |
May 21, 2026 19w ago | 8-K | $18.61 $17.09 | โผ โ8.17% | โผ โ9.83% | $24.33 (+30.74%) |
May 19, 2026 19w ago | Insider Cluster | $18.81 $18.69 | โผ โ0.64% | โผ โ1.88% | $24.33 (+29.35%) |
May 19, 2026 19w ago | Insider Cluster | $18.81 $18.69 | โฒ +0.64% | โฒ +1.88% | $24.33 (โ29.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access